The Dangers of Electronic Cigarettes: A Call for Regulation

Aug.29.2022
The Dangers of Electronic Cigarettes: A Call for Regulation
Electronic cigarette use in Brazil raises concerns despite the country's effective tobacco control policies. Potential health risks exist.

In recent years, electronic cigarettes have gained a lot of attention online, causing many people to have doubts about their safety. Despite Brazil's ban on the production and sale of electronic cigarettes since 2009, their usage has significantly increased in recent years due to their easy availability on both websites and physical storefronts.


Brazil is known as a global model for tobacco control public policy. Policies implemented over the years from 1989 to 2019 have reduced tobacco consumption among those aged 18 and over by about 60%. Some of these policies prevented children and adolescents from accessing tobacco products, thus preventing them from smoking. However, unlike all efforts to reduce smoking through public health, a new smoking trend emerged: electronic cigarettes. This includes a nicotine release device, whose first prototype was created in Pennsylvania in 1963, but it was never commercialized. In 2003, electronic cigarettes were created in China and spread around the world a decade later after a major tobacco industry company acquired a patent for them.


Many young people are drawn to the various formats, designs, and flavors of electronic cigarettes, making up a significant proportion of e-cigarette users. Research shows that in Brazil, one in five young people aged 18-24 have already used e-cigarettes. Additionally, 80% of those who use e-cigarettes are between the ages of 18 and 34. However, studies indicate that apart from nicotine, the aerosol may also contain other irritants and toxic substances such as formaldehyde, acrolein, diethylene glycol, acetaldehyde, benzene, and low doses of carcinogens. Tests on cells, tissues, and small animals exposed to liquids from different brands of e-cigarettes indicate that they are toxic to neurological, respiratory, and cardiovascular cells and may have adverse effects and cause birth defects during critical stages of fetal development.


The safety of electronic nicotine delivery systems has not been scientifically proven. In fact, the amount of nicotine dispensed by different e-cigarette devices can vary greatly, exposing consumers to much higher doses of the substance than traditional cigarettes. Reports have linked multiple incidents of severe burns, dismemberment and even death to explosions of e-cigarette batteries, dependent on the device's position at the time of detonation.


Although there is a lack of research evaluating the long-term consequences of inhaled substances from these devices, it is well-known that in the short-term, they may trigger or exacerbate symptoms of previously existing conditions such as coughing, asthma, chronic obstructive pulmonary disease (COPD), and hypertension. Additionally, in 2019, a series of severe cases of lung illness related to the use of electronic cigarettes, known as EVALI, was reported in the United States. By 2020, these cases resulted in over 2,800 hospitalizations, with many in intensive care units, and 68 deaths. The majority of cases were in young people, with one patient requiring a lung transplant.


Although the tobacco industry has attempted to convey the idea that e-cigarettes can aid in quitting smoking, this is not a good strategy. E-cigarette use operates through the same mechanism as traditional cigarettes, providing the brain with a nicotine rush. This explains why over 80% of those who use e-cigarettes to quit smoking still rely on nicotine (and e-cigarettes) after a year of follow-up. Scientifically proven and effective behavioral and pharmacological therapies are available to help quit smoking.


Since 2009, the use of electronic cigarettes has been prohibited in Brazil and will continue to be banned. However, children and teenagers are still able to obtain them, and the rate of experimentation is increasing daily. It is time to acknowledge that electronic cigarettes are not just vaporizers and to implement monitoring and restrictions on their sales.


Statement:


This article is compiled from third-party information and is intended only for industry exchange and learning.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of the content. The compilation of this article is only intended for industry discussion and research.


Due to limitations in our translation abilities, the translated article may not fully convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macau, Taiwan, and foreign related statements and positions.


The compilation of information is owned by the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
The Philippines’ Bureau of Internal Revenue is intensifying enforcement against illicit vape and tobacco products ahead of the Christmas shopping season, directing regional and enforcement offices to strengthen monitoring of production sites, warehouses, distribution channels and retail outlets. The BIR destroyed 240,550 illicit vape products in August with an estimated tax liability of about PHP1.53 billion. A nationwide tax-compliance operation in July also inspected 3,590 businesses involved in tobacco and vapor products.
Regulations
Sep.17 by 2Firsts Perspectives
Special Report|From CrossBar 20K to 6-Methyl Nicotine KUMI: Two Routes Into U.S. State Vape Directories?
Special Report|From CrossBar 20K to 6-Methyl Nicotine KUMI: Two Routes Into U.S. State Vape Directories?
Several U.S. states have incorporated the September 9, 2020 PMTA filing deadline into eligibility rules for certain vaping products. CrossBar 20K drew attention after appearing on Pennsylvania's 163-entry directory. A broader 2Firsts investigation found that related registration businesses also listed KUMI and CROSSBAR SIX products, with 171 KUMI-related entries across Louisiana, Nebraska and Wisconsin. Corporate records link Scott Silverman to Blue Nine LLC and VR Products I LLC. PMTA compliance expert Mr. K said historical applications and nicotine-analogue products may offer two different approaches to state-directory access.
Regulations
Oct.26
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia's federal government introduced a new illicit tobacco enforcement bill on September 10 that would strengthen evidentiary presumptions, representative sampling, seizure and forfeiture procedures, proceeds-of-crime powers and obligations for customs and logistics operators. The proposal follows the Combatting Illicit Tobacco Act 2026, which took effect in August and increased penalties while expanding investigative and asset-recovery tools. Together, the reforms extend Australia's crackdown from tougher criminal sanctions into import, logistics and evidentiary enforcement.
Sep.14
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives